Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis

International Journal of Artificial Organs

Volumn 37, Issue 7, 2014, Pages 521-528

  Antunes, Sandra A ^a   Vilela, Rosana Q ^b   Vaz, José D ^c   Canziani, Maria Eueĝnia F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^c Nephrology Service   (Brazil)

Author keywords

Anemia; Dialysis; Hepcidin; Inflammation; Pentoxifylline

Indexed keywords

BODY FLUIDS; DIAGNOSIS; HEMODIALYZERS; PATHOLOGY; PATIENT TREATMENT;

% REDUCTIONS; ANEMIA; ANTI-INFLAMMATORIES; C-REACTIVE PROTEINS; CHRONIC KIDNEY DISEASE; CONDITION; HAEMATOPOIESIS; HAEMODIALYSIS; HEPCIDIN; PENTOXIFYLLINE;

DIALYSIS;

HEPCIDIN; PENTOXIFYLLINE; ANTIINFLAMMATORY AGENT; FERRITIN; HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; FEMALE; HEMATOPOIESIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; AGED; ANEMIA; BLOOD; COMPLICATION; CONTROLLED STUDY; METABOLISM; MULTIMODALITY CANCER THERAPY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; FEMALE; FERRITINS; HEMOGLOBINS; HEPCIDINS; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84905269727     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000340     Document Type: Article

References (30)

1. Abreu PF, Romão Junior JE, Bastos MG. Use of erythropoiesis stimulating agents. J Bras Nefrol. 2014;36(1 Suppl 1): 19-23.
2. van der Weerd NC, Grooteman MPC, Bots ML, et al; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One. 2012;7(7):e39783.
3. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-1044.
4. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol. 1996;18(12):739-748.
5. González-Espinoza L, Rojas-Campos E, Medina-Pérez M, Peña-Quintero P, Gómez-Navarro B, Cueto-Manzano AM. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant. 2012;27(5):2023-2028.
6. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15(7):1877-1882.
7. Navarro JF, Mora C, García J, et al. Effects of pentoxifyl-line on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol. 1999;33(2): 121-125.
8. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton). 2010;15(3):344-349.
9. MacDougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5(9):1681-1689.
10. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-981.
11. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-1056.
12. Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108(4):1381-1387.
13. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
14. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol. 2008;28(1):115-121.
15. Peters HPE, Laarakkers CMM, Swinkels DW, Wetzels JFM. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010;25(3):848-853.
16. Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39(10):883-890.
17. Uehata T, Tomosugi N, Shoji T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant. 2012;27(3):1076-1083.
18. Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011;80(3):240-244.
19. Courselaud B, Troadec MB, Fruchon S, et al. Strain and gender modulate hepatic hepcidin 1 and 2 mRNA expression in mice. Blood Cells Mol Dis. 2004;32(2):283-289.
20. Ikeda Y, Tajima S, Izawa-Ishizawa Y, et al. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PLoS One. 2012;7(7):e40465.
21. Itkonen O, Parkkinen J, Stenman UH, Hämäläinen E. Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method. Clin Chim Acta. 2012;413(7/8):696-701.
22. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106(5):1864-1866.
23. Pasricha S-R, McQuilten Z, Westerman M, et al. Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica. 2011;96(8): 1099-1105.
24. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-1276.
25. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant. 2003;18(8 Suppl 8):viii17-22.
26. Tussing-Humphreys L, Pusatcioglu C, Nemeth E, Braun-schweig C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. J Acad Nutr Diet. 2012;112(3): 391-400.
27. Sarafidis PA, Rumjon A, MacLaughlin HL, MacDougall IC. Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin. Nephrol Dial Transplant. 2012;27(1):50-57.
28. Mora-Gutiérrez JM, Ferrer-Nadal A, García-Fernández N. Effect of pentoxifylline on anaemia control in haemodialysis patients: retrospective observational case-control study. Nefrologia. 2013;33(4):524-531.
29. Antunes SA, Teixeira MCB, Junior AG. Efeitos da pentoxifilina na anemia resistente à eritropoetina em pacientes sob hemodiálise. [Pentoxifylline effects on the resistant anemia to erythropoietin in hemodialysis patients] [Article in Portughese] Rev Bras Hematol Hemoter. 2008;30(4): 303-308.
30. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol. 2011;7(3):166-176.